# Surgery or Percutaneous Ablation for Liver Tumors? The Key Points Are: When, Where, and How Large

## TL;DR

The paper discusses when liver resection or ablation is better for small liver tumors, emphasizing patient-specific factors and new technologies for larger tumors.

## Contribution

The paper proposes a shift in focus from comparing overall efficacy to determining optimal treatment based on tumor location and new ablation technologies.

## Key findings

- Percutaneous ablation is preferable for central tumors due to lower complications and costs.
- Liver resection is better for subcapsular tumors where ablation cannot ensure safety margins.
- Advanced technologies like AI and stereotactic navigation are improving ablation for tumors over 3 cm.

## Abstract

Recent comparisons between liver resection (LR) and percutaneous thermal ablation (PTA) reported similar survival outcomes for tumors ≤ 3 cm in size. Therefore, the debate should regard when LR or PTA are best suited to the individual patient. Subcapsular tumors or tumors closely adjacent to critical structures should undergo LR because ablation cannot achieve an adequate safety margin. PTA should be considered the first choice to treat central tumors (located ≤ 2 cm from the capsule) because it has lower complication rates, lower costs, and shorter hospital stays. Recent technical improvements in tumor targeting and assessment of the extent of the safety margin, such as stereotactic navigation, fusion imaging, and software powered by Artificial Intelligence, are changing the approach to tumors larger than 3 cm. The next trials should be aimed at investigating up to what tumor size PTA supported by these advanced technologies can achieve outcomes comparable to LR.

The most recent comparisons between liver resection (LR) and percutaneous thermal ablation (PTA) reported similar efficacy and survival outcomes for primary and secondary liver tumors ≤ 3 cm in size. Nevertheless, LR still remains the most popular treatment strategy worldwide, and percutaneous ablation is usually reserved to patients who are not surgical candidates. However, in our opinion, the debate should no longer be what is the most effective treatment for patients with resectable small liver cancer who are not candidates for liver transplantation, but rather when LR or PTA are best suited to the individual patient. Subcapsular tumors or tumors closely adjacent to critical structures or vulnerable organs should undergo LR because ablation can often not achieve an adequate safety margin. Conversely, PTA should be considered the first choice to treat central tumors because it has lower complication rates, lower costs, and shorter hospital stay. Furthermore, recent technical improvements in tumor targeting and accurate assessment of the extent of the safety margin, such as stereotactic navigation, fusion imaging and software powered by Artificial Intelligence enabling the immediate comparison between the pre-procedure planned margins and the ablation area, are also changing the approach to tumors larger than 3 cm. The next trials should be aimed at investigating up to what tumor size PTA supported by these advanced technologies can achieve outcomes comparable to LR.